上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
(R)-PS210 纯度: 98.20%
(R)-PS210 是 PS210 的 R 对映异构体 (化合物 4h-eutomer),是 PDK1 的底物选择性变构激活剂,AC50 值为 1.8 μM。(R)-PS210 靶向 PDK1 的 PIF 结合口袋。PIF: 蛋白激酶 C 相关激酶 2 (PRK2) 相互作用片段。

(R)-PS210 Chemical Structure
CAS No. : 1410101-89-1
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
5 mg | ¥2500 | In-stock | |
10 mg | ¥3900 | In-stock | |
25 mg | ¥7800 | In-stock | |
50 mg | ¥12500 | In-stock | |
100 mg | 询价 | ||
200 mg | 询价 |
* Please select Quantity before adding items.
(R)-PS210 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Kinase Inhibitor Library
- PI3K/Akt/mTOR Compound Library
- Anti-Cancer Compound Library
- Anti-Aging Compound Library
- Oxygen Sensing Compound Library
- Glycolysis Compound Library
- Cytoskeleton Compound Library
- Anti-Pancreatic Cancer Compound Library
- Anti-Cancer Metabolism Compound Library
- Glucose Metabolism Compound Library
- Anti-Colorectal Cancer Compound Library
生物活性 |
(R)-PS210, the R enantiomer of PS210 (compound 4h-eutomer), is a substrate-selective allosteric activator of PDK1 with an AC50 value of 1.8 μM. (R)-PS210 targets to the PIF-binding pocket of PDK1. PIF: The protein kinase C-related kinase 2 (PRK2)-interacting fragment[1]. |
IC50 & Target |
AC50: 1.8 μM (PDK1)[1] |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
(R)-PS210 displays an AC50 value of 1.8 μM towards PDK1 in a Cell-Free Kinase Activity Assay. And the maximum activation of PDK1 compared to DMSO control of (R)-PS210 is 5.5 fold[1]. Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
380.31 |
||||||||||||||||
Formula |
C19H15F3O5 |
||||||||||||||||
CAS 号 |
1410101-89-1 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 230 mg/mL (604.77 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务